Suppression of prostate cancer growth by resveratrol in the transgenic rat for adenocarcinoma of prostate (TRAP) model.
Level 5 - mechanism / opinion, no new human data
Preclinical animal model (transgenic rat)
What was done
The authors tested the in vivo chemopreventive effects of resveratrol in a transgenic rat model for adenocarcinoma of the prostate (TRAP), featuring the rat probasin promoter driving the SV40 T antigen. The abstract does not specify the sample size, dosage, administration route, or duration of the intervention.
What was found
Resveratrol suppressed prostate cancer growth and induced apoptosis without observable signs of toxicity. It downregulated androgen receptor (AR) expression and suppressed mRNA levels of glandular kallikrein 11 (Gk11), an ortholog of human prostate-specific antigen (PSA). The abstract reports no numerical values, effect sizes, or statistical metrics.
Why it matters
This study provides mechanistic in vivo evidence in an animal model suggesting that resveratrol may act as a chemopreventive agent in prostate cancer via androgen receptor pathway downregulation.
Limits
Findings are restricted to a transgenic rodent model and cannot be directly translated to human clinical outcomes. The abstract provides no quantitative data, sample sizes, dosage levels, control comparisons, or statistical significance measures.
Cited by
- supports Megadoses of resveratrol decrease androgen levels in prostate cancer models.